Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-367-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120911.32.2-367-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"The effects of harmful drugs drag on for decades, with significant implications in terms of social impact, not to mention thousands of personal tragedies: the effects of dangerous drugs prescribed in the 1950s and 1960s are still visible today.
We have a moral duty to make maximum use of the potential provided by the scientific and regulatory instruments at our disposal, so as to prevent, as far as possible, any suffering and damage to health. This is also in the interests of an industry that makes a significant contribution to our economies and that must not be criminalised
where specific responsibilities lie with a small number of private managers.
For this reason, the four amendments to the directive, suggested by the Commission, are entirely reasonable and appropriate: they speed up the introduction of verification procedures and make it easier to prevent the marketing of potentially dangerous drugs, and help bring out into the open any trace of possible misconduct by companies marketing drugs that later prove to be harmful.
The supplementary provisions proposed by the rapporteur are hallmarked by greater involvement of the European Medicines Agency (EMA) and complete transparency for consumers and for the medical and scientific community as a whole. I therefore voted in favour of the report."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples